Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT01860053
Other study ID # 2030-09
Secondary ID
Status Suspended
Phase Phase 2/Phase 3
First received May 6, 2013
Last updated May 19, 2013
Start date May 2009

Study information

Verified date May 2013
Source The Miriam Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to reduce problematic vomiting and associated gastrointestinal symptoms in post-operative LAGB patients. We hypothesize that our behavioral intervention will yield greater reductions in vomiting and associated symptoms compared to our control condition.


Recruitment information / eligibility

Status Suspended
Enrollment 5
Est. completion date
Est. primary completion date February 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Age between 18 and 70 years.

2. Received LAGB surgery with either a standard Lap-Band or a standard Realize Band.

3. Report vomiting at least 3x/week.

4. Agree to allow researchers to communicate with their surgeon regarding their care.

5. Fulfilled all hospital surgery criteria.

Exclusion Criteria:

1. Report a condition that in the judgment of the Principal Investigator would render them potentially unlikely to follow the protocol (e.g., major illness, plans to move out of the area, substance abuse or other significant psychiatric problems, organic brain disease).

2. Report planning to become pregnant during the time frame of the investigation.

3. Report a history of upper gastrointestinal dismotility.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
behavioral intervention
This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.

Locations

Country Name City State
United States Weight Control and Diabetes Research Center Providence Rhode Island

Sponsors (1)

Lead Sponsor Collaborator
The Miriam Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in frequency of self-reported vomiting (number of vomiting episodes each week) measured via structured interview baseline to week 6 No
Secondary change in gastrointestinal symptom severity - questionnaire measures severity of various GI symptoms over the previous week and items are summed yielding an overall GI severity index baseline to week 6 No